ANNOUNCEMENTS

ADVANCING OPTIONS

FOR THE TREATMENT OF AML

Learn about Seattle Genetics–sponsored trials of vadastuximab talirine (SGN-CD33A; 33A) for patients with acute myeloid leukemia (AML)

ACUTE MYELOID LEUKEMIA

There is a need for a new innovative therapy in AML
Learn more

MYELOID MALIGNANCIES

CD33 has become a promising target for myeloid malignancies
Learn more

33A

A highly potent, engineered ADC designed to deliver a cytotoxic (cell-killing) agent to myeloid leukemic cells
Learn more

CLINICAL TRIALS

33A clinical trials are actively recruiting patients with AML
Learn more